🎉 M&A multiples are live!
Check it out!

Vistagen Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Vistagen Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Vistagen Therapeutics Overview

About Vistagen Therapeutics

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.


Founded

1998

HQ

United States of America
Employees

40

Website

vistagen.com

Financials

LTM Revenue $0.7M

LTM EBITDA n/a

EV

-$22.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Vistagen Therapeutics Financials

Vistagen Therapeutics has a last 12-month revenue of $0.7M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Vistagen Therapeutics achieved revenue of $1.1M and an EBITDA of -$32.5M.

Vistagen Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Vistagen Therapeutics valuation multiples based on analyst estimates

Vistagen Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue -$0.2M $1.1M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$58.7M -$32.5M XXX XXX XXX
EBITDA Margin 25819% -3050% XXX XXX XXX
Net Profit -$47.8M -$59.2M XXX XXX XXX
Net Margin 21013% -5568% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Vistagen Therapeutics Stock Performance

As of April 15, 2025, Vistagen Therapeutics's stock price is $2.

Vistagen Therapeutics has current market cap of $64.4M, and EV of -$22.5M.

See Vistagen Therapeutics trading valuation data

Vistagen Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$22.5M $64.4M XXX XXX XXX XXX $-1.73

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Vistagen Therapeutics Valuation Multiples

As of April 15, 2025, Vistagen Therapeutics has market cap of $64.4M and EV of -$22.5M.

Vistagen Therapeutics's trades at -31.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Vistagen Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Vistagen Therapeutics and 10K+ public comps

Vistagen Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$22.5M XXX XXX XXX
EV/Revenue -28.2x XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E -1.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vistagen Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Vistagen Therapeutics Valuation Multiples

Vistagen Therapeutics's NTM/LTM revenue growth is 26%

Vistagen Therapeutics's revenue per employee for the last fiscal year averaged $27K, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Vistagen Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Vistagen Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Vistagen Therapeutics and other 10K+ public comps

Vistagen Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -568% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -45% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $27K XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 1322% XXX XXX XXX XXX
R&D Expenses to Revenue 1882% XXX XXX XXX XXX
Opex to Revenue 3203% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Vistagen Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Vistagen Therapeutics M&A and Investment Activity

Vistagen Therapeutics acquired  XXX companies to date.

Last acquisition by Vistagen Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Vistagen Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Vistagen Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Vistagen Therapeutics

When was Vistagen Therapeutics founded? Vistagen Therapeutics was founded in 1998.
Where is Vistagen Therapeutics headquartered? Vistagen Therapeutics is headquartered in United States of America.
How many employees does Vistagen Therapeutics have? As of today, Vistagen Therapeutics has 40 employees.
Who is the CEO of Vistagen Therapeutics? Vistagen Therapeutics's CEO is Mr. Shawn K. Singh, J.D..
Is Vistagen Therapeutics publicy listed? Yes, Vistagen Therapeutics is a public company listed on NAS.
What is the stock symbol of Vistagen Therapeutics? Vistagen Therapeutics trades under VTGN ticker.
When did Vistagen Therapeutics go public? Vistagen Therapeutics went public in 2009.
Who are competitors of Vistagen Therapeutics? Similar companies to Vistagen Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Vistagen Therapeutics? Vistagen Therapeutics's current market cap is $64.4M
What is the current revenue of Vistagen Therapeutics? Vistagen Therapeutics's last 12-month revenue is $0.7M.
What is the current EV/Revenue multiple of Vistagen Therapeutics? Current revenue multiple of Vistagen Therapeutics is -31.8x.
What is the current revenue growth of Vistagen Therapeutics? Vistagen Therapeutics revenue growth between 2023 and 2024 was -568%.
Is Vistagen Therapeutics profitable? Yes, Vistagen Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.